Bizal Cameron E, Burns Alaina N, Feghaly Rana E El, Lee Brian R, Wirtz Ann L
Department of Pharmacy, Children's Hospital Colorado, Aurora, CO, USA.
Children's Mercy Kansas City, Kansas City, MO, USA.
Antimicrob Steward Healthc Epidemiol. 2025 Aug 15;5(1):e186. doi: 10.1017/ash.2025.10105. eCollection 2025.
To describe the antimicrobial management of and examine the etiology of intracranial suppurative infections (ISIs) at a single pediatric institution.
Retrospective review.
We included children hospitalized at a 367-bed freestanding pediatric institution for treatment of an ISI (epidural or subdural empyema, brain abscess) between January 1, 2015, and September 30, 2023. ISIs were identified using international classification of diseases 9/10 discharge diagnosis codes.
We collected data regarding patient characteristics, infection etiology and complications, antimicrobial choice and route (empiric, definitive, and outpatient), microbiology results, treatment duration, and treatment-related outcomes from the electronic health record.
A total of 72 patients met inclusion criteria. Most patients received a third- or fourth-generation cephalosporin, metronidazole, and vancomycin empirically (69.4%), while a third- or fourth-generation cephalosporin in combination with metronidazole was the most common definitive regimen (63.9%). Almost half of patients (44%) were transitioned to an entirely oral antibiotic regimen, after a median of 27 days of intravenous therapy. The median duration of antimicrobial therapy was 45 days (interquartile range = 33,56). Organisms in the group were the most common pathogens identified (62.5%). Treatment-related complications occurred in 12 (16.7%) patients.
Empiric therapy targeting resistant gram-positive organisms was not required to treat ISIs at our institution. Further data are needed on timing and requirements for oral antibiotic transition and treatment duration. In the future, there is opportunity for multi-institutional collaboration and data-sharing to determine the most appropriate management of pediatric ISIs.
描述一家儿科机构颅内化脓性感染(ISI)的抗菌药物管理情况并探究其病因。
回顾性研究。
我们纳入了2015年1月1日至2023年9月30日期间在一家拥有367张床位的独立儿科机构住院治疗ISI(硬膜外或硬膜下积脓、脑脓肿)的儿童。ISI通过国际疾病分类第9/10版出院诊断编码进行识别。
我们从电子健康记录中收集了有关患者特征、感染病因及并发症、抗菌药物选择及给药途径(经验性、确定性和门诊治疗)、微生物学结果、治疗持续时间及治疗相关结局的数据。
共有72例患者符合纳入标准。大多数患者经验性使用第三代或第四代头孢菌素、甲硝唑和万古霉素(69.4%),而第三代或第四代头孢菌素联合甲硝唑是最常见的确定性治疗方案(63.9%)。几乎一半的患者(44%)在静脉治疗中位时间27天后转为完全口服抗生素方案。抗菌治疗的中位持续时间为45天(四分位间距 = 33,56)。葡萄球菌属是最常见的病原体(62.5%)。12例(16.7%)患者发生了治疗相关并发症。
在我们机构,治疗ISI无需针对耐药革兰氏阳性菌进行经验性治疗。关于口服抗生素转换的时机和要求以及治疗持续时间,还需要更多数据。未来,有机会开展多机构合作和数据共享,以确定儿科ISI的最恰当管理方法。